D. E. Shaw & Co. Inc. Acquires 486,981 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

D. E. Shaw & Co. Inc. grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 34.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,918,340 shares of the biopharmaceutical company's stock after purchasing an additional 486,981 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.46% of Dynavax Technologies worth $24,497,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the period. Smartleaf Asset Management LLC raised its holdings in Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 2,034 shares during the period. GAMMA Investing LLC raised its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after acquiring an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies in the 4th quarter worth $71,000. Finally, Nisa Investment Advisors LLC raised its holdings in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 1,076 shares during the period. Institutional investors own 96.96% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on DVAX. StockNews.com lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. HC Wainwright restated a "buy" rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities decreased their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $24.00.

Dynavax Technologies Price Performance

DVAX stock traded up $0.11 during trading on Thursday, hitting $9.51. 1,384,656 shares of the stock traded hands, compared to its average volume of 2,218,722. Dynavax Technologies Co. has a one year low of $9.22 and a one year high of $14.63. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of 52.83 and a beta of 1.26. The company has a 50 day simple moving average of $12.06 and a 200 day simple moving average of $12.55. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Equities analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.